Control
Recent:Navarese.
Sep 30 2022 |
et al., Cardiology Journal, doi:10.5603/CJ.a2022.0072 | Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial |
| no change in mortality (p=1), 17% higher ventilation (p=1), and 3% worse recovery (p=0.8). RCT 215 hospitalized non-intensive care COVID-19 patients showing no significant difference in clinical improvement with amiodarone or verapamil. The trial, which aimed to assess the effects of ion channel inhibitors on COVID-19 progressi.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.